Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

VRCA
Verrica Pharmaceuticals Inc. Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
0.6664USD+3.833%(+0.0246)497,242
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:21:30 AM EDT
0.6500USD+1.278%(+0.0082)4,422
After-hours
May 16, 2025 4:00:30 PM EDT
0.6623USD-0.615%(-0.0041)2,060
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 16, 2021
08:20AM EST  The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street   Benzinga
Dec 15, 2021
04:06PM EST  Verrica Pharmaceuticals Announces Acceptance By FDA Of NDA Resubmission For VP-102 For The Treatment Of Molluscum Contagiosum   Benzinga
04:05PM EST  Verrica Pharmaceuticals Announces Acceptance by FDA of NDA   GlobeNewswire Inc
Nov 29, 2021
07:51AM EST  Verrica Pharma Announces Resubmission Of NDA For VP-102 For Molluscum Contagiosum   RTTNews
07:31AM EST  Verrica Pharmaceuticals Announces Resubmission Of New Drug Application For VP-102 For The Treatment Of Molluscum Contagiosum   Benzinga
07:30AM EST  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) to the U.S. Food and Drug Administration (FDA).   GlobeNewswire Inc
Nov 18, 2021
07:40AM EST  Verrica Pharma Announces FDA Acceptance Of IND Application For LTX-315 For Basal Cell Carcinoma   RTTNews
07:32AM EST  Verrica Pharma Reports FDA Accepted Its Investigational New Drug Application For LTX-315 For Treatment Of Basal Cell Carcinoma   Benzinga
07:30AM EST  Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022   GlobeNewswire Inc
Nov 12, 2021
07:46AM EST  Verrica Pharmaceuticals Q3 EPS $(0.47) Down From $(0.42) YoY   Benzinga
07:37AM EST  Verrica Pharma Q3 GAAP Net Loss $12.8 Mln Or $0.47/Shr Vs Loss Of $10.5 Mln Or $0.42/Shr Last Year   RTTNews
07:30AM EST  Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facilitys identified deficiencies from the FDA   GlobeNewswire Inc
Oct 11, 2021
03:23PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Oct 1, 2021
02:29PM EDT  Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates   Benzinga
Sep 22, 2021
08:10AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
06:05AM EDT  HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $20   Benzinga
Sep 21, 2021
02:33PM EDT  Mid-Afternoon Market Update: Dow Edges Lower; Helbiz Shares Spike Higher   Benzinga
12:13PM EDT  Mid-Day Market Update: Gold Rises 1%; Verrica Pharmaceuticals Shares Slide   Benzinga
11:35AM EDT  Why Verrica Pharmaceuticals Shares Are Trading Lower Today   Benzinga
11:14AM EDT  Mid-Morning Market Update: Markets Gain; AutoZone Earnings Beat Views   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
07:15AM EDT  RBC Capital Maintains Outperform on Verrica Pharmaceuticals, Lowers Price Target to $16   Benzinga
05:31AM EDT  Needham Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $20   Benzinga
Sep 20, 2021
07:30PM EDT  Shares of Verrica Pharmaceuticals Inc. (VRCA) tanked nearly 25% in extended session on Monday after the company received a complete response letter from the U.S. Food and Drug Administration identifying deficiencies at a contract manufacturer's facilty for VP-102.   RTTNews
04:10PM EDT  Verrica Pharma Shares To Resume Trade At 4:35 p.m. EDT   Benzinga
04:06PM EDT  Verrica Pharmaceuticals Receives Complete Response Letter From The FDA Identifying Deficiencies At A Facility Of A Contract Manufacturer For Its New Drug Application For VP-102 For The Treatment Of Molluscum Contagiosum   Benzinga
04:05PM EDT  No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer   GlobeNewswire Inc
04:01PM EDT  Verrica Pharma Shares Halted News Pending   Benzinga
Sep 19, 2021
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Aug 10, 2021
09:27AM EDT  Verrica Pharma Q2 Loss Per Share $0.43; Non-GAAP Loss Per Share $0.35   RTTNews
07:39AM EDT  Verrica Pharmaceuticals Q2 EPS $(0.35) Up From $(0.38) YoY   Benzinga
07:30AM EDT  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021.   GlobeNewswire Inc
Jul 9, 2021
07:58AM EDT  Verrica Pharma Appoints Terry Kohler As CFO   RTTNews
07:32AM EDT  Verrica Pharmaceuticals Announces Appointment Of Terry Kohler As Chief Financial Officer   Benzinga
07:30AM EDT  Company strengthens management team in anticipation ofthe potential commercial launch of VP-102, if approved   GlobeNewswire Inc
Jun 7, 2021
10:07PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
May 28, 2021
08:43AM EDT  Verrica's VP-102 Application Review for Molluscum Contagiosum Delayed till September   Benzinga
08:05AM EDT  Verrica Pharmaceuticals Inc. (VRCA) Friday said the Food and Drug Administration has extended the review period for the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum.   RTTNews
07:34AM EDT  Verrica Says FDA Extended Review Period For NDA For VP-102   RTTNews
07:32AM EDT  Verrica Pharmaceuticals Announces Extension Of FDA Review Period Of NDA For VP-102; PDUFA Date Extended To Sept. 23   Benzinga
07:30AM EDT  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021   GlobeNewswire Inc
May 26, 2021
07:30AM EDT  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 2:00 p.m. ET.   GlobeNewswire Inc
May 14, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 14, 2021   Benzinga
06:31AM EDT  RBC Capital Initiates Coverage On Verrica Pharmaceuticals with Outperform Rating, Announces Price Target of $19   Benzinga
May 12, 2021
07:30AM EDT  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.   GlobeNewswire Inc
May 7, 2021
07:38AM EDT  Verrica Pharmaceuticals Q1 EPS $(0.04) Up From $(0.39) YoY   Benzinga
07:30AM EDT  Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021   GlobeNewswire Inc
Apr 6, 2021
07:30AM EDT  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 8:45 a.m. ET.   GlobeNewswire Inc
Apr 3, 2021
02:05PM EDT  Last Week's Notable Insider Buys: PennyMac Financial, Republic Services And More   Benzinga
Mar 29, 2021
07:30AM EDT  Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verricas Chief Medical Officer, has been elected as an active member into the American Dermatological Association (ADA).   GlobeNewswire Inc
Mar 23, 2021
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
Mar 22, 2021
10:46PM EDT  Verrica Pharma Prices Public Offering Of 2.03 Mln Shares At $14.75/shr   RTTNews
09:31PM EDT  Verrica Announces Pricing of Public Offering of Common Stock   GlobeNewswire Inc
04:02PM EDT  Verrica Announces A Common Stock Offering; No Terms Disclosed   Benzinga
04:01PM EDT  Verrica Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
07:19AM EDT  Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop And Commercialize VP-102 For Molluscum And Common Warts In Japan; Torii To Make Upfront Payment Of $11.5M And Up To $58M Milestone Payments   Benzinga
07:00AM EDT  Verrica Pharmaceuticals Announces Exclusive Licensing Agreement   GlobeNewswire Inc
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
Mar 8, 2021
06:11AM EST  HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $24   Benzinga
Mar 4, 2021
07:47AM EST  Verrica Pharmaceuticals Q4 Net Loss $13.0 Mln Vs Loss $7.6 Mln Last Year   RTTNews
07:34AM EST  Verrica Pharmaceuticals Q4 EPS $(0.52) Down From $(0.31) YoY   Benzinga
07:30AM EST  FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021   GlobeNewswire Inc
Mar 3, 2021
07:30AM EST  Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place March 9-10, 2021.   GlobeNewswire Inc
Feb 17, 2021
11:39AM EST  Needham Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $22   Benzinga
07:32AM EST  Verrica Pharmaceuticals Announces FDA Filing Acceptance Of Resubmitted New Drug Application For VP-102 For The Treatment Of Molluscum Contagiosum   Benzinga
07:30AM EST  Verrica Pharmaceuticals Announces FDA Filing Acceptance of   GlobeNewswire Inc
Jan 19, 2021
07:02AM EST  Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference   Benzinga
07:00AM EST  Verrica Pharmaceuticals Presents Positive Data From Clinical   GlobeNewswire Inc
Dec 24, 2020
09:26AM EST  Biggest Price Target Changes For Thursday   Benzinga
06:17AM EST  HC Wainwright & Co. Reiterates Buy on Verrica Pharmaceuticals, Raises Price Target to $21   Benzinga
Dec 23, 2020
04:01PM EST  Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum   Benzinga
04:01PM EST  Verrica Pharmaceuticals Announces Resubmission of New Drug   GlobeNewswire Inc
Nov 17, 2020
07:32AM EST  Verrica Pharmaceuticals Announces Receipt Of Final FDA Minutes Following Type A Meeting Regarding Resubmission Of NDA For VP-102 In Molluscum; Co. Says Reaffirms Expectation To Resubmit NDA For VP-102 For The Treatment Of Molluscum In Q1 Of 2021   Benzinga
07:30AM EST  Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes   GlobeNewswire Inc
Nov 10, 2020
07:51AM EST  Verrica Reports Positive Topline Results From Phase 2 CARE-1 Clinical Study Of VP-102   RTTNews
07:34AM EST  Verrica Pharmaceuticals Announces Topline Results In Phase 2 Clinical Study Of VP-102 In Patients With External Genital Warts; Says Achieved Positive Results On Primary And Secondary Endpoints   Benzinga
07:30AM EST  - 35% of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2.4% for vehicle (p=0.0001)-   GlobeNewswire Inc
Nov 9, 2020
07:43AM EST  Verrica Pharmaceuticals Q3 EPS $(0.42) Down From $(0.24) YoY   Benzinga
07:30AM EST  - Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 -   GlobeNewswire Inc
Sep 23, 2020
04:08PM EDT  Verrica Pharmaceuticals Highlights Publication Of Results From Two Pivotal Phase III CAMP Trials   Benzinga
04:05PM EDT  JAMA Dermatology Publishes Results from Verricas   GlobeNewswire Inc
Sep 14, 2020
09:37PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
11:00AM EDT  Action Against Verrica Pharmaceuticals Inc. and Lead Plaintiff Deadline: September 14, 2020   PR Newswire
Sep 10, 2020
12:31PM EDT  Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)   PR Newswire
Sep 9, 2020
07:00PM EDT  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That   GlobeNewswire Inc
11:01AM EDT  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class   PR Newswire
11:00AM EDT  VRCA Class Action Deadline: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
07:30AM EDT  Verrica Pharmaceuticals AnnouncesParticipation in the   GlobeNewswire Inc
Sep 8, 2020
11:37AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Sep 7, 2020
04:03PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Sep 2, 2020
02:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
Aug 31, 2020
12:28PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:30AM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 29, 2020
02:37PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 27, 2020
12:30PM EDT  Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingSeptember 14, 2020deadline to file a lead plaintiff motion in the class action filed on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company")(NASDAQ: VRCA) securities between September 16, 2019 and June 29, 2020, inclusive (the Class Period).   GlobeNewswire Inc
Aug 26, 2020
03:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
10:00AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 25, 2020
09:46PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 24, 2020
12:00PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 22, 2020
11:03AM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of   PR Newswire
Aug 20, 2020
04:46PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
01:00PM EDT  Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class   PR Newswire
Aug 19, 2020
05:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
11:36AM EDT  Insider Buys Verrica Pharmaceuticals Shares   Benzinga
11:00AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 18, 2020
11:45AM EDT  Insider Buys Verrica Pharmaceuticals Stock   Benzinga
Aug 17, 2020
04:40PM EDT  Verrica Pharmaceuticals CEO White Buys 10,661 Shares @$6.28/Share   Benzinga
12:00PM EDT  VRCA Shareholder Update: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
12:00PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 15, 2020
10:10PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 13, 2020
08:18AM EDT  The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller   Benzinga
Aug 12, 2020
05:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
11:30AM EDT  Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)   PR Newswire
11:00AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 11, 2020
07:05AM EDT  Verrica Pharmaceuticals Licenses LTX-315 Oncolytic Peptide Based Immunotherapy, From Lytix Biopharma AS, For Treatment Of Dermatologic Oncology Indications   Benzinga
07:00AM EDT  Verrica Pharmaceuticals Licenses LTX-315, A First-in-Class   GlobeNewswire Inc
Aug 10, 2020
02:06PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Aug 7, 2020
12:30PM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 5, 2020
11:00AM EDT  Glancy Prongay & Murray LLP (GPM) reminds investors of the upcomingSeptember 14, 2020deadline to file a lead plaintiff motion in the class action filed on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company")(NASDAQ: VRCA) securities between September 16, 2019 and June 29, 2020, inclusive (the Class Period).   GlobeNewswire Inc
08:27AM EDT  Verrica Pharmaceuticals Q2 EPS $(0.38) Down From $(0.28) YoY   Benzinga
07:01AM EDT  - Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter -   GlobeNewswire Inc
07:01AM EDT  Verrica Pharmaceuticals Announces Option Agreement with Torii   GlobeNewswire Inc
Aug 4, 2020
04:01PM EDT  Investor Alert: Kaplan Fox Investigates Verrica Pharmaceuticals Inc. For   PR Newswire
10:00AM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Aug 3, 2020
06:42PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
12:00PM EDT  The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the   PR Newswire
Aug 2, 2020
12:45PM EDT  LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact   PR Newswire
Jul 31, 2020
12:00PM EDT  VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
Jul 30, 2020
12:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
11:30AM EDT  Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Jul 24, 2020
03:00PM EDT  The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.   GlobeNewswire Inc
Jul 23, 2020
07:31AM EDT  Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Companys product candidates   GlobeNewswire Inc
07:30AM EDT  Dr. Gary Goldenberg appointed Chief Medical Officer;Dr. Brad Catalone assumes the role of Head of Drug Development   GlobeNewswire Inc
Jul 21, 2020
07:36PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
12:00PM EDT  VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
Jul 20, 2020
08:00AM EDT  The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) investors that acquired securities between September 16, 2019 and June 29, 2020.   GlobeNewswire Inc
Jul 17, 2020
12:00PM EDT  VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC   GlobeNewswire Inc
Jul 16, 2020
11:00AM EDT  VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm   Business Wire
Jul 15, 2020
07:00PM EDT  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action   GlobeNewswire Inc
08:11AM EDT  B of A Securities Downgrades Verrica Pharmaceuticals to Neutral, Lowers Price Target to $10   Benzinga
Jul 14, 2020
11:40PM EDT  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc. ("Verrica" or the "Company")(NASDAQ:VRCA) of the September 14, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.   GlobeNewswire Inc
06:46PM EDT  The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) investors that acquired securities between September 16, 2019 and June 29, 2020.   GlobeNewswire Inc
03:26PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. (Verrica or the Company) (NASDAQ:VRCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
07:15AM EDT  Verrica Pharma Gets CRL For NDA For VP-102 For The Treatment Of Molluscum Contagiosum   RTTNews
07:06AM EDT  Verrica Pharmaceuticals Receives Complete Response Letter From FDA For Its New Drug Application For VP-102 For Treatment Of Molluscum Contagiosum   Benzinga
07:00AM EDT  Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC)and Human Factors Information   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC